Low-dose dihydroartemisinin resensitizes lung cancer cells to cisplatin by suppressing interleukin-6 release by macrophages.

Key Points

• The aim is to investigate how low-dose dihydroartemisinin (DHA) affects lung cancer cells' response to cisplatin by targeting IL-6 release.
• Used clinically relevant concentrations of DHA.
• Analyzed the roles of macrophages in IL-6 release and its impact on lung cancer cell chemoresistance.
• Explored the interaction between DHA and platinum-based chemotherapy.
• DHA significantly suppressed macrophage-derived IL-6 release.
• This suppression reduced chemoresistance in lung cancer cells.
• Combining DHA with cisplatin improved the effectiveness of the treatment.